Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 12/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3566516 | 1.00 | GCK (0.56) | GCKKCNH2L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2645847 | 0.86 | GCK (0.61) | GCKKCNH2 | |
| SCHEMBL2657160 | 0.86 | GCK (0.61) | GCKKCNH2 | |
| SCHEMBL27727445 | 0.85 | GCK (0.45) | GCKKCNH2 | |
| SCHEMBL3566769 | 0.83 | GCK (0.58) | GCKKCNH2ALDH1A1SMN1; SMN2 | |
| SCHEMBL2657056 | 0.83 | GCK (0.58) | GCKKCNH2ALDH1A1SMN1; SMN2 | |
| SCHEMBL3564270 | 0.82 | GCK (0.51) | GCKKCNH2ALDH1A1 | |
| SCHEMBL2656902 | 0.82 | GCK (0.51) | GCKKCNH2ALDH1A1 | |
| SCHEMBL2646788 | 0.81 | GCK (0.56) | GCKKCNH2 | |
| SCHEMBL2655400 | 0.81 | GCK (0.60) | GCKKCNH2L3MBTL1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2554540-A2 | 3-Cyclyl-2-(4-sulfamoyl-phenyl)-n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes | Novartis AG (CH) | 2013-02-06 | — | — | EP | claimed |
| US-7795257-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | claimed |
| US-20080318948-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | claimed |
| EP-2554540-A2 | 3-Cyclyl-2-(4-sulfamoyl-phenyl)-n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes | Novartis AG (CH) | 2013-02-06 | — | — | EP | disclosed |
| EP-1934180-B1 | 3-CYCLYL-2-(4-SULFAMOYL-PHENYL)-N-CYCLYL-PROPIONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF IMPAIRED GLUCOSE TOLERANCE AND DIABETES | NOVARTIS AG (CH) | 2012-12-05 | — | — | EP | disclosed |
| US-7795257-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-20080318948-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318948-A1 | Organic Compounds | GCK, GCKR, SLC2A2 | GCK 1/4885KCNH2 771/4885L3MBTL1 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.